Cyclo Therapeutics Inc
NASDAQ:CYTH
Cyclo Therapeutics Inc
NASDAQ:CYTH
Price:
1.421 USD
0.78%
Market Closed
Updated:
May 15, 2024
Section:
Relative Value
The Relative Value of one
CYTH
stock under the Base Case scenario is
0.563
USD.
Compared to the current market price of 1.421 USD,
Cyclo Therapeutics Inc
is
Overvalued by 60%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CYTH
Relative Value
Base Case
0.563
USD
Overvaluation 60%
Valuation Multiples
Multiples Across Competitors
CYTH Competitors Multiples
Cyclo Therapeutics Inc Competitors
Cyclo Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
40.6m USD | 37.7 | -2 | -1.6 | -1.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.1B USD | 5.3 | 60 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
171.1B USD | 5.8 | 45.5 | 19.1 | 31.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.7B USD | 11.4 | 31.1 | 25.2 | 26.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.8B USD | 8.2 | 27.9 | 22.6 | 25.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
136.7B AUD | 6.4 | 36.6 | 22.1 | 27.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.7B USD | 3 | 172.9 | 7 | 9.1 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
49.3B USD | 9.6 | -8.3 | -9.1 | -8.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
34.2B USD | 3.5 | 29.3 | 14.9 | 18.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
